• DOI:10.1016/S1474-4422(07)70220-X
Corpus ID: 24749816

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

@article{Prospero2007NeurologicalEO,
  title={Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial},
  author={N. D. Prospero and A. Baker and N. Jeffries and K. Fischbeck},
  journal={The Lancet Neurology},
  year={2007},
  volume={6},
  pages={878-886}
}

N. D. Prospero, A. Baker, +1 author K. Fischbeck

Published 2007

Medicine

The Lancet Neurology

BACKGROUND Friedreich's ataxia (FA) is a progressive, multisystem, degenerative disorder caused by a reduction in frataxin. Loss of frataxin results in mitochondrial dysfunction and oxidative damage in patients and model systems. Previous studies have indicated that the antioxidant idebenone (5 mg/kg daily) reduces cardiac hypertrophy, but definite improvement in neurological function has not been shown. METHODS 48 genetically confirmed FA patients, aged 9-17 years, were enrolled in a 6-month… CONTINUE READING

View on Elsevier

zenodo.org

Save to Library

Create Alert

Cite

Launch Research Feed